Market news

The latest update cuts the fair value price target for PDS Biotechnology from US$5.75 to US$4.75, signaling a more conservative valuation anchor for the stock. Analysts link this change to a mix of optimism around the refocused emphasis on PDS0301 and caution about funding needs, execution risks, and the structure of the Nant led financing. As you read on, you will see how these moving pieces shape the evolving story around PDS Biotechnology and what to watch next. Stay updated as the Fair...

PDS Biotechnology (PDSB) said Monday it has raised about $11.3 million from an initial closing of a

PDS Biotechnology (PDSB) said Tuesday it raised up to about $22.6 million in equity funding through

Tipranks Press Release.

PDS Biotechnology: Q2 Earnings Snapshot

PDS Biotechnology stock tanks as the company refocuses resources on its PDS0301 metastatic colorectal cancer program.